Quality of life significantly improves for women using linzagolix, alleviating symptoms associated with uterine fibroids.
Results indicate a reduction in symptom severity during treatment, making daily activities easier for affected women.
Phase 3 trials assessed the impact of linzagolix on heavy menstrual bleeding, showing positive outcomes across participants.
Findings highlight the potential benefits of linzagolix for women, supporting its use as an effective treatment option.
Abstract
"Linzagolix improves quality of life and reduces symptom severity in women with uterine fibroids (uf) who have heavy menstrual bleeding (hmb): results of two phase 3 trials"